(Unaudited data)


Development of business in the third quarter (variation at current rate)














thousands of euros1st Quarter2nd Quarter3rd Quarter
20142015Var. 15/1420142015Var. 15/1420142015Var. 15/14
France82,74989,584+ 8.3%74,26976,864+ 3.5%92,46697,767+ 5.7%
Europe (excluding France)39,96740,657+ 1.7%33,57029,943- 10.8%62,75850,614- 19.4%
North America12,66217,193+ 35.8%10,62512,894+ 21.4%13,10916,055+ 22.5%
Other countries4,8314,622- 4.3%2,9433,816+ 29.7%3,7793,594- 4.9%
Group total140,209152,056+ 8.4%121,407123,517+ 1.7%172,112168,030- 2.4%

 

thousands of euros1st Quarter2nd Quarter3rd Quarter
20142015Var. 15/1420142015Var. 15/1420142015Var. 15/14
Non-proprietary Homeopathic Medicines77,91979,191+ 1.6%73,07274,354+ 1.8%72,95773,677+ 1.0%
OTC Specialties62,19672,880+17.2%48,05849,030+ 2.0%99,02594,328- 4.7%
Other94-15-277133- 52.0%13025- 80.8%
Group total140,209152,056+ 8.4%121,407123,517+ 1.7%172,112168,030- 2.4%


Cumulative activity as of the end of september 2015

thousands of euros20142015Variation at current exchange ratesVariation at constant exchange rates
France249,484264,215+ 5.9%+ 5.9%
Europe (excluding France)136,295121,214- 11.1%- 7.1%
North America36,39646,142+ 26.8%+ 7.1%
Other countries11,55312,032+ 4.1%+ 6.7%
Group total433,728443,603+ 2.3%+ 1.9%

 

thousands of euros20142015Variation at current exchange ratesVariation at constant exchange rates
Non-proprietary Homeopathic Medicines223,948227,222+ 1.5%+ 0.5%
OTC Specialties209,279216,238+ 3.3%+ 3.6%
Other501143- 71.5%- 48.9%
Group total433,728443,603+ 2.3%+ 1.9%


Highlights of the third quarter

  • Sales revenue in the 3rd quarter of 2015 are decreasing by 2.4% in comparison to 2014 (-1% at constant rate) with a revenue growth in France and the USA, but in decline mainly in Russia and to a lesser extent in Italy and Poland.
  • Boiron announced its plan to locate its future logistic platform in the town of Les Olmes, near Tarare in the West of Lyon. Meanwhile, construction work for the site extension of Messimy have begun.
  • Boiron put on the French market a new cough syrup, Stodaline®.


Outlook

  • Boiron continues its involvement in the development of homeopathy in the world.
  • Given the development of the activity at the end of September 2015 and the unpredictability of seasonal pathology of the last quarter, the operational income may not reach the same level as in 2014.


Our next update: January 21, 2016 at market close, publication of the sales revenue for the year 2015.
Person responsible for financial information: Christian Boiron
Contact for financial information: Véronique Bouscayrol
Investor relations: +33 (0) 4.78.45.63.43 - e-mail : boironfinances@boiron.fr
ISIN Code: FR0000061129 (BOI) - Bloomberg: BOI FP - Reuters: BOIR.PA
The group's financial information is online at: www.boironfinance.com

Information réglementée
Communiqués au titre de l′obligation d′information permanente :
- Communiqué sur comptes, résultats, chiffres d′affaires
Full and original press release in PDF:
http://www.actusnews.com/documents_communiques/ACTUS-0-41752-BOI-161015-CA-T3-15-GB.pdf
© Copyright Actusnews Wire
Recevez gratuitement par email les prochains communiqués de la société en vous inscrivant sur www.actusnews.com
Receive by email the next press releases of the company by registering on www.actusnews.com, it′s free


© 2015 ActusNews